

CLEARBRIDGE HEALTH LIMITED
(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES

Pursuant to Rule 706A of the Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”) of the Singapore Exchange Securities Trading Limited, the Board of Directors (the “**Board**” or “**Directors**”) of Clearbridge Health Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to announce the following changes in the Group’s structure during the six-month financial period from 1 January 2025 to 30 June 2025.

STRIKING-OFF OF DORMANT SUBSIDIARY IN MALAYSIA

Clearbridge Medica Sdn. Bhd., a dormant subsidiary of the Group, has been struck off from the Register of Companies of Malaysia under Section 550 of the Companies Act 2016, effective from 10 March 2025 (the “**Strike-Off**”).

The Strike-Off is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 December 2025.

INCORPORATION OF A SUBSIDIARY IN SINGAPORE

On 30 May 2025, the Company incorporated a wholly-owned subsidiary in Singapore known as CellTrust Bio Singapore Pte. Ltd. (“**CBS**”) (the “**SG Incorporation**”).

CBS has an issued and paid-up share capital of 2 Singapore Dollars and its principal activity is investment holding.

The SG Incorporation was funded through internal resources and it is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 December 2025.

INCORPORATION OF A SUBSIDIARY IN HONG KONG

On 23 June 2025, CBS incorporated a wholly-owned subsidiary in Hong Kong known as RedDot Holding Co. Limited (“**RHC**”) (the “**HK Incorporation**”).

RHC has an issued and paid-up share capital of 10,000 Hong Kong Dollars and its principal activity is provision of marketing services.

The HK Incorporation was funded through internal resources and it is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 December 2025.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

31 July 2025

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.